Approximately 15–20% of non-small cell lung cancer (NSCLC) patient tumors have activating epidermal growth factor receptor (EGFR) mutations5, of which exon 19 deletions (E746-A750, ~54%) and L858R mutations (~41%) are predominant6. This evidence concerns the gene EGFR and non-small cell lung carcinoma.